Aerovate Therapeutics halts Phase 3 PAH trial, launches strategic alternatives review with Wedbush

Jade Biosciences, Inc.

Previously halted enrollment and shut down Phase 3 IMPAHCT trial and long-term extension study.
Now conducting comprehensive review of strategic alternatives to maximize shareholder value.
Engaged Wedbush PacGrow as exclusive strategic financial advisor for the review process.
Alternatives may include acquisition, merger, reverse merger, business combination, or liquidation.
No timetable set and no assurance any transaction will result from the review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.